Investigational & Alternative Treatments for PLS

There are no disease-modifying drugs approved for Primary Lateral Sclerosis. That is the honest foundation. But it does not mean nothing is being tried. Across the motor neuron disease field, dozens of experimental approaches are under active investigation — emerging drugs in clinical trials, gene therapies targeting specific mutations, stem cell approaches, neuromodulation techniques, and medications used off-label for symptom relief. This section maps all of it, with honest evidence levels at every step.

Why this page exists

Patients and families living with PLS want to understand what is being tried, what might be coming, and what some clinicians explore outside the standard of care. The internet provides plenty of information about investigational treatments for ALS — but almost nothing that filters it through the lens of PLS specifically, or distinguishes clearly between what is real, what is early, and what is speculative.

PLS is predominantly an upper motor neuron disease. Most drug research in the MND field is focused on ALS, which involves both upper and lower motor neurons. That distinction matters: a drug targeting lower motor neuron pathology in ALS may have no relevance to PLS at all. Throughout this section, we are explicit about which conditions a given approach targets, and how plausible any extension to PLS might be.

None of the approaches on these pages are recommended treatments for PLS. They are what is being studied, what is being tried in some clinical contexts, and what the evidence actually shows — so you can have an informed conversation with your neurologist rather than arriving with a printout from a news story.

How to read the evidence levels

Each drug, therapy, and approach in this section carries an evidence level label. These are not arbitrary — they reflect the quality and quantity of published evidence, the relevance to PLS specifically, and the stage of development. Here is what each label means:

• Strong — Multiple well-designed controlled trials or consistent evidence across studies, directly in PLS or in the closest applicable population. Rarely applies to investigational treatments; most strong-evidence treatments are on the current treatments page.
• Emerging — At least one Phase 2 or Phase 3 trial with positive signals, or consistent evidence in related MND conditions that plausibly extends to PLS. Promising but not yet conclusive.
• Limited — Phase 1 safety data, small trials, or positive signals that have not yet been confirmed in larger studies. Something to watch, not something to act on.
• Anecdotal — Case reports, patient reports, or clinical experience without controlled trial evidence. Sometimes used in practice; impossible to evaluate without data.
• Theoretical — Plausible scientific rationale from preclinical data or disease mechanism, but no meaningful clinical evidence yet. Included for completeness, not as a recommendation.

Emerging drugs in trials

The ALS and MND drug pipeline is more active in 2026 than at any prior point in the history of the disease. Drugs targeting synaptic dysfunction, neuroinflammation, motor neuron hyperexcitability, protein misfolding, oxidative stress, and bioenergetic failure are all in active clinical trials. Most are studied primarily in ALS — but some have mechanisms that are plausible in upper motor neuron disease, and a few are being studied in the broader MND spectrum.

Notable candidates include pridopidine (sigma-1 receptor activator, Phase 3 PREVAiLS trial enrolling as of 2026), PrimeC (ciprofloxacin/celecoxib combination, Phase 3 PARAGON trial), CNM-Au8 (gold nanocrystals targeting bioenergetics), QRL-101 (potassium channel opener for motor neuron hyperexcitability), QRL-201 (ASO targeting stathmin-2 restoration), and SPG302 (synaptic regenerative compound). Evidence levels, mechanisms, and PLS relevance are covered in detail on the dedicated page.

Emerging drugs in trials: full overview →

Gene therapy & antisense oligonucleotides

Gene-targeted therapy represents one of the most significant advances in ALS medicine in the last decade. Tofersen (Qalsody), an antisense oligonucleotide that silences the toxic SOD1 gene, became the first FDA-approved gene therapy for ALS in 2023. It works only for the approximately 2% of ALS patients with a SOD1 mutation — and has no applicability to PLS. But the approval demonstrated a proof of concept: gene targeting in motor neuron disease is possible.

Other ASO programs target FUS mutations (ulefnersen), C9orf72 repeat expansions, and stathmin-2 restoration in TDP-43 pathology. CRISPR gene editing approaches are in early preclinical stages. For PLS, the honest reality is that no causative gene has been identified for adult-onset sporadic PLS — the form most patients have — which means there is currently no gene therapy target. Juvenile PLS (caused by ALS2 mutations) is a different story with future potential.

Gene therapy & ASOs: full overview →

Stem cell research

Stem cell therapy for motor neuron disease has been studied in Phase 1 and Phase 2 trials using several different cell types and delivery approaches. The leading clinical program — Cedars-Sinai's CNS10-NPC-GDNF trial using GDNF-delivering neural progenitor cells — completed Phase 1/2a with a favorable safety profile and early signs of biological activity. No stem cell therapy has been approved for ALS or PLS.

A serious and important warning applies to this area: unregulated "stem cell clinics" offering treatments outside of clinical trials are widespread, expensive, and potentially dangerous. They prey specifically on patients with serious neurological diagnoses. The dedicated page covers this directly.

Stem cell research: full overview →

Neuromodulation & rehabilitation technology

Non-invasive brain stimulation and advanced rehabilitation technologies represent a different class of investigational approach — not targeting disease biology, but attempting to compensate for or modulate the upper motor neuron dysfunction that defines PLS. Transcranial direct current stimulation (tDCS) has been evaluated in ALS in a randomized trial with promising results. Robot-aided gait training (Lokomat) has been studied in a 2021 PLS case report with meaningful functional improvements. Repetitive transcranial magnetic stimulation (rTMS) is under investigation. These approaches have the strongest theoretical applicability to PLS of any category, precisely because PLS is a pure upper motor neuron disease and cortical modulation is directly relevant.

Neuromodulation & rehab technology: full overview →

Cannabis & CBD

Cannabinoids are one of the most commonly asked-about symptom treatments in motor neuron disease — partly because pharmaceutical cannabinoids (specifically nabiximols, brand name Sativex) have decent evidence for spasticity reduction, and partly because many patients were already using cannabis recreationally before their diagnosis. The CANALS trial (Riva et al., Lancet Neurology 2019) is the anchor piece of MND-specific evidence: a 60-patient Phase 2 RCT that found a modest but statistically significant spasticity reduction with nabiximols over six weeks. PLS patients were included in the cohort.

The crucial distinction is between THC and CBD. THC produces both the chronic spasticity benefit and an acute motor-coordination impairment that can make walking dramatically worse in someone whose upper motor neuron function is already compromised. CBD delivers some of the spasticity benefit without the acute motor hit. For patients with PLS, this distinction matters enormously.

Cannabis & CBD: full overview →

Off-label & supportive medications

Off-label prescribing — using medications approved for other conditions to address symptoms in PLS — is common in clinical practice, even though controlled evidence specifically in PLS is limited. For muscle cramps, mexiletine has solid evidence from ALS trials and is sometimes used in PLS. For sialorrhea, botulinum toxin injections and various anticholinergic agents are used off-label with good clinical rationale. For fatigue, modafinil and bupropion are occasionally tried. For pseudobulbar affect before Nuedexta, amitriptyline and SSRIs have a long history of off-label use. This page documents what clinicians sometimes try, what the evidence actually shows, and where the limits of that evidence are.

Off-label & supportive medications: full overview →

Important caveats

Before reading any of the detailed pages in this section, there are several things worth keeping in mind:

• None of these are proven treatments for PLS. Some have good evidence in ALS; none has been tested in a controlled PLS-specific trial (except where explicitly noted). Extrapolation from ALS to PLS is uncertain, even for drugs that target upper motor neuron mechanisms.
• Do not self-administer investigational drugs. Medications outside of approved indications carry risks that are only manageable in a clinical context with proper monitoring. This applies to drugs mentioned in news articles, obtained overseas, or found through patient communities.
• Clinical trial participation is a legitimate path. If you are interested in accessing investigational treatments, trial participation is the safest and most scientifically productive way to do so. See the clinical trials page for how to find and assess trials.
• Be skeptical of commercial claims. The overlap between genuine research and commercial exploitation of desperate patients is real, particularly in stem cell therapy and some supplement markets. If a provider is offering something not available in clinical trials, for a fee, treat that as a serious red flag.
• Your neurologist is the right person to discuss any of this with. A specialist familiar with your specific disease course can tell you which approaches are irrelevant to your situation, which might be worth asking about, and which trials you might be eligible for.

What to ask your doctor